Valuation: Cellectar Biosciences, Inc.

Market Cap 12.1M 10.78M 9.98M 9.03M 17.02M 1.14B 17.22M 120M 46.96M 600M 45.39M 44.44M 1.91B P/E 2026 *
-0.53x
P/E 2027 * -0.67x
Enterprise Value 12.1M 10.78M 9.98M 9.03M 17.02M 1.14B 17.22M 120M 46.96M 600M 45.39M 44.44M 1.91B EV / Sales 2026 *
-
EV / Sales 2027 * 1.58x
Free-Float
98.25%
Yield 2026 *
-
Yield 2027 * -
10-15 Cellectar Biosciences, Inc. Presents Efficacy Results From Phase 2b CLOVER WaM Subset Analysis Of Iopofosine I 131 In Patients Relapsed/Refractory To BTK Inhibitor Therapy CI
09-29 Cellectar Biosciences Announces Subset Analysis of Data from Phase 2 Clover Wam Clinical Trial of iopofosine I 131 in Patients Refractory or Resistant to BTK Inhibitor Therapy CI
08-18 Cellectar Biosciences, Inc. - Special Call
08-13 Cellectar Biosciences, Inc., Q2 2026 Earnings Call, Aug 13, 2026
08-13 Cellectar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
06-01 Cellectar Biosciences Highlights New Efficacy Data from Phase 2B Clover Wam Study of Iopofosine I 131 in Relapsed or Refractory Waldenström Macroglobulinemia CI
05-20 Cellectar Biosciences Files for Secondary Offering of Common Shares MT
05-18 Cellectar Biosciences, Inc. Announces Board Changes CI
05-14 Cellectar Biosciences, Inc., Q1 2026 Earnings Call, May 14, 2026
05-14 Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Cellectar Biosciences, Inc. announced that it has received $30.708034 million in funding from Balyasny Asset Management L.P., Nantahala Capital Management, LLC, Caligan Partners, LP, Janus Henderson Investors US LLC, Silverarc Capital Management, LLC and other investors CI
05-05 Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2B Clover Wam Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in Relapsed or Refractory Waldenström Macroglobulinemia CI
05-05 Cellectar Biosciences, Inc. Appoints Andrew Gu to Board of Directors CI

Last Transcript: Cellectar Biosciences, Inc.

1 day+4.07%
1 week+8.47%
Current month-30.43%
1 month-45.53%
3 months-50.39%
6 months-54.93%
Current year-56.61%
1 week 1.12
Extreme 1.12
1.33
1 month 1.12
Extreme 1.12
2.31
Current year 1.12
Extreme 1.12
4.7
1 year 1.12
Extreme 1.12
4.7
3 years 1.12
Extreme 1.12
133.5
5 years 1.12
Extreme 1.12
309
10 years 1.12
Extreme 1.12
9,210.01
Manager TitleAgeSince
Chief Executive Officer 67 15/06/2015
Director of Finance/CFO 61 28/05/2014
Chief Operating Officer 53 23/02/2022
Director TitleAgeSince
Director/Board Member 57 01/02/2008
Director/Board Member 67 15/06/2015
Chairman 56 01/08/2017
Date Insider Type Main position Quantity % Market Cap. Importance
7/8/26 A Free

Director

15,000 0.5603%
7/8/26 A Free

Director

15,000 0.5603%
7/7/26 A Free

Director

25,000 0.9339%
Change 5-day change 1-year change 3-year change Capi.($)
+4.07%+8.47%-69.60%-98.38% 12.1M
-1.01%+5.13%+58.93%+117.36% 1,133B
-0.61%+1.52%+34.34%+68.48% 621B
-1.48%+0.47%+23.08%+94.76% 503B
-0.93%+2.19%+38.32%+63.33% 379B
+1.07%+1.70%+71.06%+45.98% 370B
+0.26%+0.97%+21.23%+50.44% 292B
-0.33%-1.09%+0.16%+24.36% 262B
-0.14%+2.87%+45.56%+57.22% 237B
-1.88%+0.02%+23.77%+97.39% 190B
Average +0.18%+3.74%+24.69%+52.09% 398.8B
Weighted average by Cap. +0.16%+3.73%+40.64%+79.59%

Financials

2026 *2027 *
Net sales - 7.65M 6.82M 6.31M 5.71M 10.76M 722M 10.89M 75.66M 29.69M 379M 28.69M 28.1M 1.21B
Net income -31.63M -28.19M -26.1M -23.62M -44.49M -2.98B -45.02M -313M -123M -1.57B -119M -116M -5B -37.38M -33.31M -30.84M -27.91M -52.57M -3.53B -53.2M -370M -145M -1.85B -140M -137M -5.91B
Net Debt - -
Projected Income Statement - Annual - Cellectar Biosciences, Inc.
Logo Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Employees
11
Date Price Change Volume
21/10/26 $1.280 +4.07% 134,955
20/10/26 $1.230 +9.82% 109,491
19/10/26 $1.120 -1.75% 195,300
16/10/26 $1.140 -4.20% 341,330
15/10/26 $1.190 +0.85% 382,262
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cellectar Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.280USD
Average target price
11.50USD
Spread / Average Target
+798.44%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cellectar Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. CLRB Stock